



DIABETES

*Some important facts from Central and Eastern Europe,
Central Asia and Central America.*



When talking about diabetes arises, its gravity is still widely under recognized. According to the latest estimates, under the present trend, the number of persons with diabetes will double, from 154 million to 300 million in the next 25 years.

The greater share of this increase will probably take place in the developing countries, which are the nations which can least afford it. As a specialized CRO for Eastern Europe and Central America, we would like to show you some interesting figures on the current development of diabetes in these regions. As they are not always the main focus of the pharmaceutical industry, its figures are not always well known. The **Russian Federation** for example holds over 10 million of the total

population suffering from diabetes, and medical estimates say this figure will rise by 65% in the next 20 years. In the **Czech Republic** there are 315.000 diabetes patients, which is 3% of the population. A similar situation can be found in **Slovakia**. In the **Ukraine** it is a 7,5% of the total population who suffers from diabetes. By 2025 the ratio will rise by an expected 60% and will archive the figure of 4,5 million. In **Poland**, with a population of 39 million people, nearly 1,5 million are sick with diabetes and the number of cases will rise by 65% until 2025. In the Baltic Countries of **Latvia** and **Lithuania** nearly 3% of the population suffer from this disease, with an estimated rise of 60%. In **Belarus**, with a population of more than 10 million, there is a 7% of diabetes patients, and this will rise by 62% by 2025. In **Bulgaria** and **Romania** more than 3% of the total population suffer from diabetes. The situation in **Guatemala** is alarming: more than 2,12% of the population are dealing with diabetes and according to the latest expectations, this will rise by 136% until 2025. In **Mexico**, with a population of nearly 100 million, almost 5 million suffer from diabetes. Medical estimations say this ratio will rise by 126% until the year 2025.

Therefore, all of the abovementioned facts are the reason for worldwide intensive efforts in clinical investigation to fight against this increasingly growing disease. The aim is to optimize the existing therapy concepts and also to reach the effective prevention of the characteristic late effects of diabetes. Diabetes is one of the main focuses of S&P Pharmatest for the successful performance of clinical studies. Through our successful organization of the most different clinical trials phases II and III, we have built a competitive and efficient network of trial centres in Central and Eastern Europe, as well as in Central Asia and Central America. We proudly would like to indicate you that not only the quality of the data is absolutely impeccable thanks to intensive professional training and care measures, but also, and mostly, that **the recruitment speed of naïve untreated patients is correct and nearly 5 times faster than in comparable specialized Western-located diabetes centres**. Within our regional project and monitoring teams, many diabetes specialist are currently working. All of them ensure a rapid development and a high quality of the trials and projects in various countries in Central and Eastern Europe, Central Asia and Central America. The centres in our diabetes network do have a patient-pool of average 200-500 newly diagnosed patients per year each in their database. They are also audit certified, and are prepared to take on your study. All the diabetes centres working with us do have all the necessary laboratory equipment and diagnosis possibilities for clinical trials on the indication diabetes. If you are interested in studies in Eastern Europe, we will be happy to prepare a specific feasibility report for your planned or ongoing study, in order to speed up your project and bring it to a successful accordance with your planned timeline.

Thus we are taking the liberty of sending you a brief questionnaire on the next page which we ask you to fax back if interested.

Yours truly,

Dr. Alexander Siebel
Medical & Managing Director

www.pharmatest.net



Your opinion is important for us. We would like to know what you think of us and our reports, so please take a few minutes to fill up this short questionnaire and fax it back to us (+49 30 6937500). By helping us, we become better for you.

1. Do you have R&D experience in Central and Eastern Europe?

- Not at all, Poor, Reliable, Good, Excellent

If yes, in which countries? And on which indications?

2. For which indication would you like to receive more detailed information on Central and Eastern Europe?

- HIV / Immunology, Oncology, Diabetes, Gastroenterology, Urology, CNS (e.g. Alzheimer), Dermatology, Infectiology (e.g. Hepatitis C, chronic bronchitis), Cardiology, Ophthalmology, Gynaecology, Other

3. For the study approval process in which of these countries would you like to receive further information?

- Bulgaria, Croatia, Czech Rep., Hungary, Mexico, Latvia, Lithuania, Poland, Romania, Guatemala, Russia, Slovakia, Ukraine, Argentina, Other

4. What clinical R&D fields are most important for you to be covered in Central and Eastern Europe?

Table with 4 columns: Very important, Important, Also significant, Secondary. Rows include Phase I-IV, Local-based project management, Study approval services, etc.

5. What are the qualities you value the most for your choice of Central and Eastern Europe?

Table with 4 columns: Very important, Important, Also significant, Secondary. Rows include High recruitment rates, Significant savings in timeline, Fast permission for study, etc.

Name: Company: Department / Position: Phone: Fax: E-mail: